Recent progress in vaccination against human papillomavirus-mediated cervical cancer

Reviews in Medical Virology

Volumn 25, Issue S1, 2015, Pages 54-71

  Mckee, Sara J ^a   Bergot, Anne Sophie ^a   Leggatt, Graham R ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

DRUG EFFICACY; HUMAN; NONHUMAN; PAPILLOMA VIRUS; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; UTERINE CERVIX CANCER; VACCINATION; VIRUS LIKE AGENT; VIRUS STRAIN; WART VIRUS; ANIMAL; FEMALE; GENETICS; IMMUNOLOGY; MALE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PHYSIOLOGY; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

ANIMALS; FEMALE; HUMANS; MALE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 84924051246     PISSN: 10529276     EISSN: 10991654     Source Type: Journal    
DOI: 10.1002/rmv.1824     Document Type: Review

References (169)

1. Bhat P, Mattarollo SR, Gosmann C, Frazer IH, Leggatt GR. Regulation of immune responses to HPV infection and during HPV-directed immunotherapy. Immunological Reviews 2011; 239: 85-98.
2. Leggatt GR, Frazer IH. HPV vaccines: the beginning of the end for cervical cancer. Current Opinion in Immunology 2007; 19: 232-238.
3. Vajdic CM, van Leeuwen MT. Cancer incidence and risk factors after solid organ transplantation. International Journal of Cancer 2009; 125: 1747-1754.
4. Frazer IH, Leggatt GR, Mattarollo SR. Prevention and treatment of papillomavirus-related cancers through immunization. Annual Review of Immunology 2011; 29: 111-138.
5. Mollers M, Vossen JM, Scherpenisse M, van der Klis FR, Meijer CJ, de Melker HE. Review: current knowledge on the role of HPV antibodies after natural infection and vaccination: implications for monitoring an HPV vaccination programme. Journal of Medical Virology 2013; 85: 1379-1385.
6. Suzich JA, Ghim SJ, Palmer-Hill FJ, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proceedings of the National Academy of Sciences of the United States of America 1995; 92: 11553-11557.
7. Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991; 185: 251-257.
8. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proceedings of the National Academy of Sciences of the United States of America 1992; 89: 12180-12184.
9. Zhao Q, Allen MJ, Wang Y, et al. Disassembly and reassembly improves morphology and thermal stability of human papillomavirus type 16 virus-like particles. Nanomedicine: Nanotechnology, Biology and Medicine 2012; 8: 1182-1189.
10. Zhao Q, Modis Y, High K, et al. Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity. Virology Journal 2012; 9: 52.
11. Breitburd F, Kirnbauer R, Hubbert NL, et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. Journal of Virology 1995; 69: 3959-3963.
12. Stanley M, Pinto LA, Trimble C. Human papillomavirus vaccines--immune responses. Vaccine 2012; 30(Suppl 5): F83-87.
13. Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012; 30(Suppl 5): F123-138.
14. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374: 301-314.
15. Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007; 369: 1861-1868.
16. Dillner J, Kjaer SK, Wheeler CM, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010; 341: c3493.
17. Munoz N, Kjaer SK, Sigurdsson K, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. Journal of the National Cancer Institute 2010; 102: 325-339.
18. Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. The Lancet Oncology 2012; 13: 89-99.
19. Kreimer AR, Gonzalez P, Katki HA, et al. Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. The Lancet Oncology 2011; 12: 862-870.
20. Einstein MH, Baron M, Levin MJ, et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Human Vaccines 2009; 5: 705-719.
21. Einstein MH, Baron M, Levin MJ, et al. Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years. Human Vaccines 2011; 7: 1359-1373.
22. Day PM, Kines RC, Thompson CD, et al. In vivo mechanisms of vaccine-induced protection against HPV infection. Cell Host & Microbe 2010; 8: 260-270.
23. Schiller JT, Day PM, Kines RC. Current understanding of the mechanism of HPV infection. Gynecologic Oncology 2010; 118: S12-17.
24. zur Hausen H. Immortalization of human cells and their malignant conversion by high risk human papillomavirus genotypes. Seminars in Cancer Biology 1999; 9: 405-411.
25. Markowitz LE, Tsu V, Deeks SL, et al. Human papillomavirus vaccine introduction--the first five years. Vaccine 2012; 30(Suppl 5): F139-148.
26. Malagon T, Drolet M, Boily MC, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. The Lancet Infectious Diseases 2012; 12: 781-789.
27. Mesher D, Soldan K, Howell-Jones R, et al. Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England. Vaccine 2013; 32: 26-32.
28. Hibbitts S, Tristram A, Beer H, et al. UK population based study to predict impact of HPV vaccination. Journal of Clinical Virology: The Official Publication of the Pan American Society for Clinical Virology 2014; 59: 109-114.
29. Sando N, Kofoed K, Zachariae C, Fouchard J. A reduced national incidence of anogenital warts in young danish men and women after introduction of a national quadrivalent human papillomavirus vaccination programme for young women-an ecological study. Acta Dermato-Venereologica 2014; 94: 288-292.
30. Ali H, Donovan B, Wand H, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ 2013; 346: f2032.
31. Perez-Castro S, Lorenzo-Mahia Y, Inarrea Fernandez A, et al. Cervical intraepithelial neoplasia grade 2 or worse in Galicia, Spain: HPV 16 prevalence and vaccination impact. Enfermedades Infecciosas y Microbiología Clínica 2013; 32: 479-485.
32. Gertig DM, Brotherton JM, Budd AC, Drennan K, Chappell G, Saville AM. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Medicine 2013; 11: 227.
33. Yoshikawa H, Ebihara K, Tanaka Y, Noda K. Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18-26 years. Cancer Science 2013; 104: 465-472.
34. Li R, Li Y, Radley D, et al. Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, double-blind, placebo-controlled trial in Chinese males and females. Vaccine 2012; 30: 4284-4291.
35. Bhatla N, Suri V, Basu P, et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women. The Journal of Obstetrics and Gynaecology Research 2010; 36: 123-132.
36. Clark LR, Myers ER, Huh W, et al. Clinical trial experience with prophylactic human papillomavirus 6/11/16/18 vaccine in young black women. The Journal of Adolescent Health: Official Publication of the Society for Adolescent Medicine 2013; 52: 322-329.
37. Aponte-Gonzalez J, Fajardo-Bernal L, Diaz J, Eslava-Schmalbach J, Gamboa O, Hay JW. Cost-effectiveness analysis of the bivalent and quadrivalent human papillomavirus vaccines from a societal perspective in Colombia. PLoS One 2013; 8: e80639.
38. Noronha AS, Markowitz LE, Dunne EF. Systematic review of human papillomavirus vaccine coadministration. Vaccine 2014; 32: 2670-2674.
39. Kreimer AR, Rodriguez AC, Hildesheim A, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. Journal of the National Cancer Institute 2011; 103: 1444-1451.
40. Romanowski B, Schwarz TF, Ferguson LM, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Human Vaccines 2011; 7: 1374-1386.
41. Lazcano-Ponce E, Stanley M, Munoz N, et al. Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months. Vaccine 2014; 32: 725-732.
42. Dobson SR, McNeil S, Dionne M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA 2013; 309: 1793-1802.
43. Smolen KK, Gelinas L, Franzen L, et al. Age of recipient and number of doses differentially impact human B and T cell immune memory responses to HPV vaccination. Vaccine 2012; 30: 3572-3579.
44. Safaeian M, Porras C, Pan Y, et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prevention Research 2013; 6: 1242-1250.
45. Nelson EA, Lam HS, Choi KC, et al. A pilot randomized study to assess immunogenicity, reactogenicity, safety and tolerability of two human papillomavirus vaccines administered intramuscularly and intradermally to females aged 18-26 years. Vaccine 2013; 31: 3452-3460.
46. Huo Z, Bissett SL, Giemza R, Beddows S, Oeser C, Lewis DJ. Systemic and mucosal immune responses to sublingual or intramuscular human papilloma virus antigens in healthy female volunteers. PLoS One 2012; 7: e33736.
47. Clayton J. Clinical approval: trials of an anticancer jab. Nature 2012; 488: S4-6.
48. Rowhani-Rahbar A, Alvarez FB, Bryan JT, et al. Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine. Journal of Clinical Virology: The Official Publication of the Pan American Society for Clinical Virology 2012; 53: 239-243.
49. Schwarz TF. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix. Advances in Therapy 2009; 26: 983-998.
50. Macartney KK, Chiu C, Georgousakis M, Brotherton JM. Safety of human papillomavirus vaccines: a review. Drug Safety: An International Journal of Medical Toxicology and Drug Experience 2013; 36: 393-412.
51. Luna J, Plata M, Gonzalez M, et al. Long-term follow-up observation of the safety, immunogenicity, and effectiveness of gardasil in adult women. PLoS One 2013; 8: e83431.
52. Moreira ED, Jr., Palefsky JM, Giuliano AR, et al. Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral-like-particle vaccine in older adolescents and young adults. Human Vaccines 2011; 7: 768-775.
53. Grimaldi-Bensouda L, Guillemot D, Godeau B, et al. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects. Journal of Internal Medicine 2014; 275: 398-408.
54. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007; 370: 890-907.
55. Wheeler CM, Castellsague X, Garland SM, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. The Lancet Oncology 2012; 13: 100-110.
56. Bissett SL, Draper E, Myers RE, Godi A, Beddows S. Cross-neutralizing antibodies elicited by the Cervarix human papillomavirus vaccine display a range of Alpha-9 inter-type specificities. Vaccine 2014; 32: 1139-1146.
57. Ahmed AI, Bissett SL, Beddows S. Amino acid sequence diversity of the major human papillomavirus capsid protein: implications for current and next generation vaccines. Infection, Genetics and Evolution 2013; 18: 151-159.
58. Schiller JT, Nardelli-Haefliger D. Chapter 17: second generation HPV vaccines to prevent cervical cancer. Vaccine 2006; 24(Suppl 3): S3/147-153.
59. HPV vaccine works against nine viral types. Cancer Discovery 2014; 4: OF2.
60. Wang JW, Roden RB. Virus-like particles for the prevention of human papillomavirus-associated malignancies. Expert Review of Vaccines 2013; 12: 129-141.
61. Gambhira R, Gravitt PE, Bossis I, Stern PL, Viscidi RP, Roden RB. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species. Cancer Research 2006; 66: 11120-11124.
62. Tyler M, Tumban E, Chackerian B. Second-generation prophylactic HPV vaccines: successes and challenges. Expert Review of Vaccines 2014; 13: 247-255.
63. Tumban E, Peabody J, Peabody DS, Chackerian B. A universal virus-like particle-based vaccine for human papillomavirus: longevity of protection and role of endogenous and exogenous adjuvants. Vaccine 2013; 31: 4647-4654.
64. Jagu S, Kwak K, Karanam B, et al. Optimization of multimeric human papillomavirus L2 vaccines. PLoS One 2013; 8: e55538.
65. Schellenbacher C, Kwak K, Fink D, et al. Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses. The Journal of Investigative Dermatology 2013; 133: 2706-2713.
66. McGrath M, de Villiers GK, Shephard E, Hitzeroth II, Rybicki EP. Development of human papillomavirus chimaeric L1/L2 candidate vaccines. Archives of Virology 2013; 158: 2079-2088.
67. Schellenbacher C, Roden R, Kirnbauer R. Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines. Journal of Virology 2009; 83: 10085-10095.
68. Jagu S, Kwak K, Garcea RL, Roden RB. Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection. Vaccine 2010; 28: 4478-4486.
69. Singharoy A, Polavarapu A, Joshi H, Baik MH, Ortoleva P. Epitope fluctuations in the human papillomavirus are under dynamic allosteric control: a computational evaluation of a new vaccine design strategy. Journal of the American Chemical Society 2013; 135: 18458-18468.
70. Hu YM, Huang SJ, Chu K, et al. Safety of an Escherichia coli-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine: An open-label phase I clinical trial. Human Vaccines & Immunotherapeutics 2014; 10: 469-475.
71. Kim D, Gambhira R, Karanam B, et al. Generation and characterization of a preventive and therapeutic HPV DNA vaccine. Vaccine 2008; 26: 351-360.
72. Hitzeroth, II, Passmore JA, Shephard E, et al. Immunogenicity of an HPV-16 L2 DNA vaccine. Vaccine 2009; 27: 6432-6434.
73. Liu WJ, Zhao KN, Gao FG, Leggatt GR, Fernando GJ, Frazer IH. Polynucleotide viral vaccines: codon optimisation and ubiquitin conjugation enhances prophylactic and therapeutic efficacy. Vaccine 2001; 20: 862-869.
74. Roehr B. US committee recommends HPV vaccine for boys. BMJ 2011; 343: d7068.
75. Moreira ED, Jr., Giuliano AR, Palefsky J, et al. Incidence, Clearance and Progression to Disease of Genital Human Papillomavirus Infection in Heterosexual Men. The Journal of Infectious Diseases 2014; 210: 192-199.
76. Zou H, Tabrizi SN, Grulich AE, et al. Early acquisition of anogenital human papillomavirus among teenage men who have sex with men. Journal of Infectious Diseases 2014; 209: 642-651.
77. Lebelo RL, Boulet G, Nkosi CM, Bida MN, Bogers JP, Mphahlele MJ. Diversity of HPV types in cancerous and pre-cancerous penile lesions of South African men: Implications for future HPV vaccination strategies. Journal of Medical Virology 2014; 86: 257-265.
78. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. The New England Journal of Medicine 2011; 364: 401-411.
79. Stanley M. Perspective: Vaccinate boys too. Nature 2012; 488: S10.
80. Toft L, Storgaard M, Muller M, et al. Comparison of the immunogenicity and reactogenicity of cervarix and gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial. The Journal of Infectious Diseases 2014; 209: 1165-1173.
81. Berenson AB, Patel PR, Barrett AD. Is administration of the HPV vaccine during pregnancy feasible in the future? Expert Review of Vaccines 2014; 13: 213-219.
82. Shah KV. A case for immunization of human papillomavirus (HPV) 6/11-infected pregnant women with the quadrivalent HPV vaccine to prevent juvenile-onset laryngeal papilloma. Journal of Infectious Diseases 2014; 209: 1307-1309.
83. Berenson AB, Male E, Lee TG, et al. Assessing the need for and acceptability of a free-of-charge postpartum HPV vaccination program. American Journal of Obstetrics and Gynecology 2014; 210: 213 e211-217.
84. Diaz-Padilla I, Monk BJ, Mackay HJ, Oaknin A. Treatment of metastatic cervical cancer: future directions involving targeted agents. Critical Reviews in Oncology/Hematology 2013; 85: 303-314.
85. Hung CF, Ma B, Monie A, Tsen SW, Wu TC. Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opinion on Biological Therapy 2008; 8: 421-439.
86. Lin K, Doolan K, Hung CF, Wu TC. Perspectives for preventive and therapeutic HPV vaccines. Journal of the Formosan Medical Association 2010; 109: 4-24.
87. Ma B, Maraj B, Tran NP, et al. Emerging human papillomavirus vaccines. Expert Opinion on Emerging Drugs 2012; 17: 469-492.
88. Bergot AS, Kassianos A, Frazer IH, Mittal D. New approaches to immunotherapy for HPV associated cancers. Cancers (Basel) 2011; 3: 3461-3495.
89. Kenter GG, Welters MJ, Valentijn AR, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. The New England Journal of Medicine 2009; 361: 1838-1847.
90. Daayana S, Elkord E, Winters U, et al. Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. British Journal of Cancer 2010; 102: 1129-1136.
91. Monroy-Garcia A, Gomez-Lim MA, Weiss-Steider B, et al. Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model. Archives of Virology 2014; 159: 291-305.
92. Kaufmann AM, Nieland JD, Jochmus I, et al. Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3). International Journal of Cancer 2007; 121: 2794-2800.
93. Da Silva DM, Schiller JT, Kast WM. Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines. Vaccine 2003; 21: 3219-3227.
94. Jemon K, Young V, Wilson M, et al. An enhanced heterologous virus-like particle for human papillomavirus type 16 tumour immunotherapy. PLoS One 2013; 8: e66866.
95. Liu XS, Xu Y, Hardy L, et al. IL-10 mediates suppression of the CD8 T cell IFN-gamma response to a novel viral epitope in a primed host. Journal of Immunology 2003; 171: 4765-4772.
96. Liu XS, Dyer J, Leggatt GR, et al. Overcoming original antigenic sin to generate new CD8 T cell IFN-gamma responses in an antigen-experienced host. Journal of Immunology 2006; 177: 2873-2879.
97. Liu XS, Leerberg J, MacDonald K, Leggatt GR, Frazer IH. IFN-gamma promotes generation of IL-10 secreting CD4+ T cells that suppress generation of CD8 responses in an antigen-experienced host. Journal of Immunology 2009; 183: 51-58.
98. Draghiciu O, Walczak M, Hoogeboom BN, et al. Therapeutic immunization and local low-dose tumor irradiation, a reinforcing combination. International Journal of Cancer 2014; 134: 859-872.
99. Rothman J, Paterson Y. Live-attenuated Listeria-based immunotherapy. Expert Review of Vaccines 2013; 12: 493-504.
100. Grasso F, Negri DR, Mochi S, et al. Successful therapeutic vaccination with integrase defective lentiviral vector expressing nononcogenic human papillomavirus E7 protein. International Journal of Cancer 2013; 132: 335-344.
101. Zong J, Wang C, Liu B, et al. Human hsp70 and HPV16 oE7 fusion protein vaccine induces an effective antitumor efficacy. Oncology Reports 2013; 30: 407-412.
102. Sadraeian M, Rasoul-Amini S, Mansoorkhani MJ, Mohkam M, Ghoshoon MB, Ghasemi Y. Induction of antitumor immunity against cervical cancer by protein HPV-16 E7 in fusion with ricin B chain in tumor-bearing mice. International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society 2013; 23: 809-814.
103. Sadraeian M, Khoshnood Mansoorkhani MJ, Mohkam M, Rasoul-Amini S, Hesaraki M, Ghasemi Y. Prevention and inhibition of TC-1 cell growth in tumor bearing mice by HPV16 E7 protein in fusion with shiga toxin b-subunit from shigella dysenteriae. Cell Journal 2013; 15: 176-181.
104. Liu TY, Hussein WM, Jia Z, et al. Self-adjuvanting polymer-peptide conjugates as therapeutic vaccine candidates against cervical cancer. Biomacromolecules 2013; 14: 2798-2806.
105. Kim H, Kwon B, Sin JI. Combined stimulation of IL-2 and 4-1BB receptors augments the antitumor activity of E7 DNA vaccines by increasing ag-specific CTL responses. PLoS One 2013; 8: e83765.
106. Han KT, Sin JI. DNA vaccines targeting human papillomavirus-associated diseases: progresses in animal and clinical studies. Clinical and Experimental Vaccine Research 2013; 2: 106-114.
107. Diniz MO, Cariri FA, Aps LR, Ferreira LC. Enhanced therapeutic effects conferred by an experimental DNA vaccine targeting human papillomavirus-induced tumors. Human Gene Therapy 2013; 24: 861-870.
108. Villarreal D, Wise MC, Walters JN, et al. Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity. Cancer Research 2014; 74: 1789-1800.
109. Peng S, Lyford-Pike S, Akpeng B, et al. Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine. Cancer Immunology, Immunotherapy: CII 2013; 62: 171-182.
110. van Meir H, Kenter GG, Burggraaf J, et al. The need for improvement of the treatment of advanced and metastatic cervical cancer, the rationale for combined chemo-immunotherapy. Anti-Cancer Agents in Medicinal Chemistry 2014; 14: 190-203.
111. Frazer IH, Quinn M, Nicklin JL, et al. Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia. Vaccine 2004; 23: 172-181.
112. Stewart TJ, Drane D, Malliaros J, et al. ISCOMATRIX adjuvant: an adjuvant suitable for use in anticancer vaccines. Vaccine 2004; 22: 3738-3743.
113. Morelli AB, Becher D, Koernig S, Silva A, Drane D, Maraskovsky E. ISCOMATRIX: a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases. Journal of Medical Microbiology 2012; 61: 935-943.
114. Domingos-Pereira S, Decrausaz L, Derre L, et al. Intravaginal TLR agonists increase local vaccine-specific CD8 T cells and human papillomavirus-associated genital-tumor regression in mice. Mucosal Immunology 2013; 6: 393-404.
115. Stahl-Hennig C, Eisenblatter M, Jasny E, et al. Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques. PLoS Pathogens 2009; 5: e1000373.
116. Van Doorslaer K, Reimers LL, Studentsov YY, Einstein MH, Burk RD. Serological response to an HPV16 E7 based therapeutic vaccine in women with high-grade cervical dysplasia. Gynecologic Oncology 2010; 116: 208-212.
117. Bilu D, Sauder DN. Imiquimod: modes of action. British Journal of Dermatology 2003; 149(Suppl 66): 5-8.
118. Chuang CM, Monie A, Hung CF, Wu TC. Treatment with imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination. Journal of Biomedical Science 2010; 17: 32.
119. Daftarian P, Mansour M, Benoit AC, et al. Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion. Vaccine 2006; 24: 5235-5244.
120. Wang HL, Xu H, Lu WH, Zhu L, Yu YH, Hong FZ. In vitro and in vivo evaluations of human papillomavirus type 16 (HPV16)-derived peptide-loaded dendritic cells (DCs) with a CpG oligodeoxynucleotide (CpG-ODN) adjuvant as tumor vaccines for immunotherapy of cervical cancer. Archives of Gynecology and Obstetrics 2014; 289: 155-162.
121. Zwaveling S, Ferreira Mota SC, Nouta J, et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. Journal of Immunology 2002; 169: 350-358.
122. Burchell AN, Winer RL, de Sanjose S, Franco EL. Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. Vaccine 2006; 24(Suppl 3): S3/52-61.
123. Perez O, Romeu B, Cabrera O, et al. Adjuvants are key factors for the development of future vaccines: lessons from the finlay adjuvant platform. Frontiers in Immunology 2013; 4: 407.
124. Mattarollo SR, Rahimpour A, Choyce A, Godfrey DI, Leggatt GR, Frazer IH. Invariant NKT cells in hyperplastic skin induce a local immune suppressive environment by IFN-gamma production. Journal of Immunology 2010; 184: 1242-1250.
125. Choyce A, Yong M, Narayan S, et al. Expression of a single, viral oncoprotein in skin epithelium is sufficient to recruit lymphocytes. PLoS One 2013; 8: e57798.
126. Mittal D, Kassianos AJ, Tran LS, et al. Indoleamine 2, 3-dioxygenase activity contributes to local immune suppression in the skin expressing human papillomavirus oncoprotein e7. The Journal of Investigative Dermatology 2013; 133: 2686-2694.
127. Kim D, Hung CF, Wu TC, Park YM. DNA vaccine with alpha-galactosylceramide at prime phase enhances anti-tumor immunity after boosting with antigen-expressing dendritic cells. Vaccine 2010; 28: 7297-7305.
128. Stewart TJ, Smyth MJ, Fernando GJ, Frazer IH, Leggatt GR. Inhibition of early tumor growth requires J alpha 18-positive (natural killer T) cells. Cancer Research 2003; 63: 3058-3060.
129. Peghini BC, Abdalla DR, Barcelos AC, Teodoro L, Murta EF, Michelin MA. Local cytokine profiles of patients with cervical intraepithelial and invasive neoplasia. Human Immunology 2012; 73: 920-926.
130. Scott ME, Ma Y, Kuzmich L, Moscicki AB. Diminished IFN-gamma and IL-10 and elevated Foxp3 mRNA expression in the cervix are associated with CIN 2 or 3. International Journal of Cancer 2009; 124: 1379-1383.
131. Molling JW, de Gruijl TD, Glim J, et al. CD4(+)CD25hi regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia. International Journal of Cancer 2007; 121: 1749-1755.
132. van der Burg SH, Piersma SJ, de Jong A, et al. Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens. Proceedings of the National Academy of Sciences of the United States of America 2007; 104: 12087-12092.
133. Zhou F, Frazer IH, Leggatt GR. Keratinocytes efficiently process endogenous antigens for cytotoxic T-cell mediated lysis. Experimental Dermatology 2009; 18: 1053-1059.
134. Zhou F, Leggatt GR, Frazer IH. Human papillomavirus 16 E7 protein inhibits interferon-gamma-mediated enhancement of keratinocyte antigen processing and T-cell lysis. The FEBS Journal 2011; 278: 955-963.
135. Leggatt GR, Dunn LA, De Kluyver RL, Stewart T, Frazer IH. Interferon-gamma enhances cytotoxic T lymphocyte recognition of endogenous peptide in keratinocytes without lowering the requirement for surface peptide. Immunology and Cell Biology 2002; 80: 415-424.
136. Fowler NL, Frazer IH. Mutations in TAP genes are common in cervical carcinomas. Gynecologic Oncology 2004; 92: 914-921.
137. Park JS, Kim EJ, Kwon HJ, Hwang ES, Namkoong SE, Um SJ. Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis. The Journal of Biological Chemistry 2000; 275: 6764-6769.
138. Perea SE, Massimi P, Banks L. Human papillomavirus type 16 E7 impairs the activation of the interferon regulatory factor-1. International Journal of Molecular Medicine 2000; 5: 661-666.
139. Zhou F, Chen J, Zhao KN. Human papillomavirus 16-encoded E7 protein inhibits IFN-gamma-mediated MHC class I antigen presentation and CTL-induced lysis by blocking IRF-1 expression in mouse keratinocytes. The Journal of General Virology 2013; 94: 2504-2514.
140. Frazer IH, Thomas R, Zhou J, et al. Potential strategies utilised by papillomavirus to evade host immunity. Immunological Reviews 1999; 168: 131-142.
141. Tindle RW. Immune evasion in human papillomavirus-associated cervical cancer. Nature Reviews. Cancer 2002; 2: 59-65.
142. Maciag PC, Radulovic S, Rothman J. The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine 2009; 27: 3975-3983.
143. REALISTIC: A phase I, dose escalation trial of recombinant listeria monocytogenes (Lm)-based vaccine encoding human papilloma virus genotype 16 target antigens (ADXS11-001) in patients with HPV-16 +ve oropharyngeal carcinoma safety. ClinicalTrials.gov.
144. Randomized, single blind, placebo controlled phase 2 study to assess the safety of ADXS11-001 for the treatment of cervical intraepithelial neoplasia grade 2/3. ClinicalTrials.gov.
145. A phase II evaluation of ADXS11-001 (NSC 752718, BB-IND#13, 712) in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix. ClinicalTrials.gov.
146. Transgene and roche modify the clinical development programme for their HPV-targeted immunotherapy TG4001/R3484. http://www.transgene.fr/index.php?option=com_content&view=article&id=33%3Apressreleases&catid=7%3Ainvestors-media&Itemid=56&lang=en [07/01/2014].
147. Transgene reports randomized phase 2b data with its therapeutic HPV vaccine TG4001 in women with CIN2/3 intraepithelial cervical neoplasia. 2012. http://www.transgene.fr/?option=com_content&view=article&id=59&Itemid=73&lang=en [07/01/2014].
148. Brun JL, Dalstein V, Leveque J, et al. Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy. American Journal of Obstetrics and Gynecology 2011; 204: 169 e161-168.
149. Kenter GG, Welters MJ, Valentijn AR, et al. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2008; 14: 169-177.
150. Welters MJ, Kenter GG, Piersma SJ, et al. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2008; 14: 178-187.
151. de Vos van Steenwijk PJ, Ramwadhdoebe TH, Lowik MJ, et al. A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions. Cancer Immunology, Immunotherapy: CII 2012; 61: 1485-1492.
152. Anderson JS, Hoy J, Hillman R, et al. A randomized, placebo-controlled, dose-escalation study to determine the safety, tolerability, and immunogenicity of an HPV-16 therapeutic vaccine in HIV-positive participants with oncogenic HPV infection of the anus. Journal of Acquired Immune Deficiency Syndromes 2009; 52: 371-381.
153. A multicenter, nonrandomized, open-label phase 1 safety study of HspE7 and poly-ICLC administered concomitantly in cervical intraepithelial neoplasia (CIN) subjects. ClinicalTrials.gov.
154. Matijevic M, Hedley ML, Urban RG, Chicz RM, Lajoie C, Luby TM. Immunization with a poly (lactide co-glycolide) encapsulated plasmid DNA expressing antigenic regions of HPV 16 and 18 results in an increase in the precursor frequency of T cells that respond to epitopes from HPV 16, 18, 6 and 11. Cellular Immunology 2011; 270: 62-69.
155. Phase I open label, dose escalation study to evaluate the safety, tolerability and immunogenicity of human papillomavirus (HPV) DNA plasmid (VGX-3100) + electroporation (EP) in adult females post surgical or ablative treatment of grade 2 or 3 cervical intraepithelial neoplasia (CIN). ClinicalTrials.gov.
156. Phase I, Open-label Study to Evaluate the Safety, Tolerability and Immunogenicity of a Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation (EP) in Adult Females Previously Immunized With VGX-3100. ClinicalTrials.gov.
157. Phase II placebo controlled study of VGX-3100, (HPV16 E6/E7, HPV18 E6/E7 DNA Vaccine) delivered IM followed by electroporation with cellectra-5P for the treatment of biopsy-proven CIN 2/3 or CIN 3 with documented HPV 16 or 18.: ClinicalTrials.gov.
158. Santin AD, Bellone S, Palmieri M, et al. Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. Journal of Virology 2008; 82: 1968-1979.
159. A pilot study of pnGVL4a-CRT/E7 (Detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2/3 (CIN2/3). ClinicalTrials.gov.
160. A phase I efficacy and safety study of HPV16-specific therapeutic DNA-vaccinia vaccination in combination with topical imiquimod, in patients with HPV16+ high grade cervical dysplasia (CIN3). ClinicalTrials.gov.
161. A phase 2 study of ipilimumab in women with metastatic or recurrent HPV-related cervical carcinoma of either squamous cell or adenocarcinoma histologies. ClinicalTrials.gov.
162. Phase II evaluation of adjuvant hyperfractionated radiation and docetaxel for intermediate risk HPV associated oropharynx cancer. ClinicalTrials.gov.
163. A phase II study of lymphodepletion followed by autologous tumor-infiltrating lymphocytes and high-dose aldesleukin for human papillomavirus-associated cancers. ClinicalTrials.gov.
164. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2011; 29: 4294-4301.
165. Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2011; 17: 4550-4557.
166. Phase II study of de-intensification of radiation and chemotherapy for low-risk HPV-related oropharyngeal squamous cell carcinoma. ClinicalTrials.gov.
167. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. The New England Journal of Medicine 2010; 363: 24-35.
168. Reduced-intensity therapy for advanced oropharyngeal cancer in non-smoking human papilloma virus (HPV)-16 positive patients. ClinicalTrials.gov.
169. TROG12.01 a randomised trial of weekly cetuximab and radiation versus weekly cisplatin and radiation in good prognosis locoregionally advanced HPV-associated oropharyngeal squamous cell carcinoma. ClinicalTrials.gov.